Tm-Values and Unfolded Fraction Can Predict Aggregation Rates for Granulocyte Colony Stimulating Factor Variant Formulations but Not under Predominantly Native Conditions.
暂无分享,去创建一个
Paul A Dalby | Paul Matejtschuk | Adrian F Bristow | P. Dalby | Mathew J Robinson | A. Bristow | P. Matejtschuk
[1] C. Kolvenbach,et al. Granulocyte‐colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2 , 2009 .
[2] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[3] V. Uversky,et al. Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.
[4] S. Radford,et al. Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. , 2005, Journal of molecular biology.
[5] Bradford Stanley,et al. Control of Protein Particle Formation During Ultrafiltration/Diafiltration Through Interfacial Protection , 2014, Journal of pharmaceutical sciences.
[6] Massimo Morbidelli,et al. Population balance modeling of antibodies aggregation kinetics. , 2012, The journal of physical chemistry. B.
[7] Naresh Chennamsetty,et al. Predictive tools for stabilization of therapeutic proteins , 2009, mAbs.
[8] J. Straub,et al. Propensity to form amyloid fibrils is encoded as excitations in the free energy landscape of monomeric proteins. , 2014, Journal of molecular biology.
[9] Ashley C. Gucinski,et al. Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers , 2014, Analytical and Bioanalytical Chemistry.
[10] Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor , 2012, Biotechnology Letters.
[11] J. Cayuela,et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements , 2007, Leukemia.
[12] W. Jiskoot,et al. Aggregation and Immunogenicity of Therapeutic Proteins , 2010 .
[13] D. Lauffenburger,et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.
[14] Michael J. Pikal,et al. Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice , 1997, Pharmaceutical Research.
[15] Andreas Zimmer,et al. Evaluating the effects of buffer conditions and extremolytes on thermostability of granulocyte colony-stimulating factor using high-throughput screening combined with design of experiments. , 2012, International journal of pharmaceutics.
[16] D Eisenberg,et al. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] Xuejun Han,et al. Protein aggregation kinetics during Protein A chromatography. Case study for an Fc fusion protein. , 2007, Journal of chromatography. A.
[18] Paul A Dalby,et al. Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment. , 2016, Molecular pharmaceutics.
[19] Theodore W Randolph,et al. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. , 2002, Biochemistry.
[20] T. Boone,et al. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. , 1996, Pharmaceutical biotechnology.
[21] L. Regan,et al. Reengineering Granulocyte Colony-stimulating Factor for Enhanced Stability* , 2001, The Journal of Biological Chemistry.
[22] R. Tierney,et al. Optimization of the formulation for a candidate lyophilised tetanus toxoid reference preparation. , 2009, Biologicals : journal of the International Association of Biological Standardization.
[23] C. Dobson. Protein folding and misfolding , 2003, Nature.
[24] Theodore W Randolph,et al. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.
[25] A. Hubbard,et al. Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials , 2007, Analytical and bioanalytical chemistry.
[26] S. Vignesh,et al. Mutational Analysis on Human Granulocyte Macrophage-Colony Stimulating Factor Stability Using Computational Approaches , 2015 .
[27] W Wang,et al. Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.
[28] Paul Matejtschuk,et al. A comparison of vials with ampoules for the storage of biological reference materials. , 2005, Biologicals : journal of the International Association of Biological Standardization.
[29] D. Lauffenburger,et al. Parsing the Effects of Binding, Signaling, and Trafficking on the Mitogenic Potencies of Granulocyte Colony‐Stimulating Factor Analogues , 2003, Biotechnology progress.
[30] J. King,et al. Aggregation of granulocyte‐colony stimulating factor in vitro involves a conformationally altered monomeric state , 2005, Protein science : a publication of the Protein Society.
[31] Vidyashankara G. Iyer,et al. High throughput prediction of the long-term stability of pharmaceutical macromolecules from short-term multi-instrument spectroscopic data. , 2014, Journal of pharmaceutical sciences.
[32] A. Fersht,et al. Conformational entropy of alanine versus glycine in protein denatured states , 2007, Proceedings of the National Academy of Sciences.
[33] Anirban Kundu,et al. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening , 2002, Protein science : a publication of the Protein Society.